Champions Oncology, Inc. (CSBR) SEC filings

CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30

Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 9/30241% above fair value

$4.65−0.13 (-2.72%)

Close on Nov 12, 2026Market cap $64.72MP/E –Yield –

SEC filings

40 of Champions Oncology's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Oct 14, 2026	Oct 16, 2026	SEC EDGAR
Quarterly report	10-Q	Jul 31, 2026	Sep 11, 2026	SEC EDGAR
Current report	8-K	Sep 10, 2026	Sep 10, 2026	SEC EDGAR
Proxy statement	DEF 14A	Aug 27, 2026	Aug 28, 2026	SEC EDGAR
Annual report	10-K	Apr 30, 2026	Jul 27, 2026	SEC EDGAR
Current report	8-K	Jul 27, 2026	Jul 27, 2026	SEC EDGAR
Current report	8-K	Mar 24, 2026	Mar 30, 2026	SEC EDGAR
Quarterly report	10-Q	Jan 31, 2026	Mar 12, 2026	SEC EDGAR
Current report	8-K	Mar 12, 2026	Mar 12, 2026	SEC EDGAR
Quarterly report	10-Q	Oct 31, 2025	Dec 15, 2025	SEC EDGAR
Current report	8-K	Dec 15, 2025	Dec 15, 2025	SEC EDGAR
Current report	8-K	Oct 16, 2025	Oct 16, 2025	SEC EDGAR
Quarterly report	10-Q	Jul 31, 2025	Sep 15, 2025	SEC EDGAR
Current report	8-K	Sep 15, 2025	Sep 15, 2025	SEC EDGAR
Proxy statement	DEF 14A	Aug 22, 2025	Aug 22, 2025	SEC EDGAR
Annual report	10-K	Apr 30, 2025	Jul 23, 2025	SEC EDGAR
Current report	8-K	Jul 23, 2025	Jul 23, 2025	SEC EDGAR
Current report	8-K	Jul 21, 2025	Jul 21, 2025	SEC EDGAR
Quarterly report	10-Q	Jan 31, 2025	Mar 17, 2025	SEC EDGAR
Current report	8-K	Mar 11, 2025	Mar 11, 2025	SEC EDGAR
Quarterly report	10-Q	Oct 31, 2024	Dec 16, 2024	SEC EDGAR
Current report	8-K	Dec 11, 2024	Dec 11, 2024	SEC EDGAR
Current report	8-K	Oct 14, 2024	Oct 15, 2024	SEC EDGAR
Current report	8-K	Oct 3, 2024	Oct 3, 2024	SEC EDGAR
Quarterly report	10-Q	Jul 31, 2024	Sep 13, 2024	SEC EDGAR
Current report	8-K	Sep 11, 2024	Sep 11, 2024	SEC EDGAR
Proxy statement	DEF 14A	Aug 27, 2024	Aug 27, 2024	SEC EDGAR
Annual report	10-K	Apr 30, 2024	Jul 19, 2024	SEC EDGAR
Current report	8-K	Jul 18, 2024	Jul 18, 2024	SEC EDGAR
Quarterly report	10-Q	Jan 31, 2024	Mar 15, 2024	SEC EDGAR
Current report	8-K	Mar 12, 2024	Mar 12, 2024	SEC EDGAR
Quarterly report	10-Q	Oct 31, 2023	Dec 13, 2023	SEC EDGAR
Current report	8-K	Dec 12, 2023	Dec 12, 2023	SEC EDGAR
Current report	8-K	Oct 19, 2023	Oct 19, 2023	SEC EDGAR
Current report	8-K	Oct 9, 2023	Oct 17, 2023	SEC EDGAR
Quarterly report	10-Q	Jul 31, 2023	Sep 13, 2023	SEC EDGAR
Current report	8-K	Sep 13, 2023	Sep 13, 2023	SEC EDGAR
Proxy statement	DEF 14A	Aug 28, 2023	Aug 28, 2023	SEC EDGAR
Annual report	10-K	Apr 30, 2023	Jul 24, 2023	SEC EDGAR
Current report	8-K	Jul 24, 2023	Jul 24, 2023	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Champions Oncology's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-12 reverse split on Aug 12, 2015
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CSBR.

Compare: CSBR vs CGEN · CSBR vs RXRX · CSBR vs STRO · CSBR vs BDTX · CSBR vs ADAPY

Revenue growth6.7% · median -55.6%

Operating margin-1.7% · median -265.0%

Net margin-1.8% · median -344.2%

Company	Revenue	Growth
RXRX	$68.23M	+56.2%
ADAPY	$65.09M	-54.0%
CSBR	$60.66M	+6.7%
STRO	$45.11M	-57.3%
CGEN	–	–
BDTX	$0	-100.0%

Company

Next earnings (est.): Dec 14, 2026, after close
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: April 30
Employees: 214
Held by institutions: 42.4%
Auditor: EISNERAMPER LLP
SEC CIK: 771856

Advertisement
300 × 250

See a number that looks wrong?